Janssen's Oral IL-23R Antagonist Succeeds in Phase III Trials; Everest Medicines' Nefecon Fully Approved in South Korea
Johnson & Johnson
Medical Device R&D and Manufacturer
Everest Medicines
Developer of Innovative Therapies
VelaVigo
Innovative Drug Developer
He Eye
Ophthalmology Medical Service Provider
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
BeOne
Developer of Molecular Targeted and Immune Anti-Tumor Drugs
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
A $20 Billion Market Stirs Again.
On November 18, Johnson & Johnson announced positive key results from the Phase III ICONIC-LEAD study of the oral IL-23R antagonist Icotrokinra (JNJ-2113) for the treatment of plaque psoriasis (PsO). This is the first oral IL-23R targeted drug to successfully complete a Phase III study.
Everest Medicines Has New Progress.
On November 19, Everest Medicines announced that the South Korean Ministry of Food and Drug Safety has fully approved the company's new drug application for the marketing authorization of budesonide enteric-coated capsules, intended for the treatment of adult patients with primary immunoglobulin A nephropathy.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Orange Sail Pharmaceuticals' Nectin4/TROP2 Bispecific Antibody ADC Achieves Overseas Licensing
On November 18, Orange Sails Pharmaceuticals announced a global strategic collaboration agreement with Avenzo Therapeutics. The latter has obtained the rights to the company’s Nectin4/TROP2 bispecific antibody-drug conjugate (ADC) worldwide (excluding Greater China), and Orange Sails Pharmaceuticals will receive up to 50 million US dollars in upfront and near-term milestone payments.
2) Biosion Licenses Out Two Drugs Overseas
On November 18, Biosion announced that it had entered into an exclusive global licensing agreement (excluding Greater China) with Aclaris Therapeutics for the TSLP monoclonal antibody BSI-045B and the TSLP/IL4R bispecific antibody BSI-502. Biosion will receive over $40 million in cash payments but will bear part of the development costs and drug product material expenses. Biosion will also obtain 19.9% equity in Aclaris Therapeutics.
/ 02 /
Capital Information
1) He Eye: Shareholder Advanced Manufacturing Fund Plans to Reduce Company Shares by No More Than 2%
On November 19, He Eye announced that shareholder Advanced Manufacturing Fund plans to reduce its shares in the company by no more than 3.1061 million within three months after fifteen trading days from the disclosure of this announcement, accounting for 2% of the company's total share capital excluding the number of shares in the repurchase special securities account.
/ 03 /
Pharmaceutical News
1) Hengrui Pharma's SHR-4394 for Injection Receives Clinical Approval
On November 19, according to the CDE website, Hengrui Pharma's SHR-4394 injection received clinical approval and is planned to be studied for the treatment of prostate cancer.
2) BeOne Medicines' BGB-58067 Tablets Granted Clinical Approval
On November 19, according to the CDE website, BeOne Medicines' BGB-58067 tablets received clinical approval for the treatment of patients with advanced solid tumors.
3) Betta Pharmaceuticals' Injectable MCLA-129 Receives Clinical Approval
On November 19, according to the CDE website, Betta Pharmaceuticals' injectable MCLA-129 received clinical approval and is intended for the treatment of patients with advanced solid tumors.
4) Zai Lab's Injectable ZL-1310 Receives Clinical Approval
On November 19, according to the CDE website, Zai Lab's injectable ZL-1310 received clinical approval and is intended for the treatment of small cell lung cancer patients.
5) 3SBio Submits IL-17A Monoclonal Antibody for Marketing Approval
On November 18, 3SBio announced that the marketing application for its recombinant anti-IL-17A humanized monoclonal antibody injection (608) had been accepted by the CDE for the treatment of adult patients with moderate to severe plaque psoriasis.
6) Everest Medicines' Nefukang Fully Approved in South Korea
On November 19, Everest Medicines announced that the South Korean Ministry of Food and Drug Safety has fully approved the company's new drug application for the marketing authorization of budesonide enteric-coated capsules, intended for the treatment of adult patients with primary immunoglobulin A nephropathy.
/ 04 /
Instrument Tracking
1) Kangxi Biotech Collagen Cartilage Regeneration Carrier Registration Terminated
On November 19, according to the NMPA website, Kangxi Biotech's collagen protein cartilage regeneration carrier has terminated registration.
2) Hengrui Pharma's Peripheral Balloon Dilation Catheter Receives Registration Approval
On November 19, according to the NMPA website, Hengrui Pharma's Desino Peripheral Balloon Dilatation Catheter received registration approval.
3) Yunhe Photoelectric Semiconductor Laser Therapy Device Obtains Registration Approval
On November 19, according to the NMPA website, Yunhe Photoelectric Semiconductor Laser Therapy Device received registration approval.
/ 05 /
Digital Healthcare Daily
1) Airdoc's Diabetic Retinopathy Fundus Image Auxiliary Diagnosis Software Receives Registration Approval
On November 19, according to the NMPA website, Airdoc Medical's diabetic retinopathy fundus image auxiliary diagnosis software received registration approval.
/ 06 /
Overseas Pharma News
1) Johnson & Johnson's Oral IL-23R Antagonist Achieves Positive Key Results in Two Phase III Studies
On November 18, Johnson & Johnson announced positive key results from the Phase III ICONIC-LEAD study of the oral IL-23R antagonist Icotrokinra (JNJ-2113) for the treatment of plaque psoriasis (PsO). This is the first oral IL-23R targeted drug to successfully complete a Phase III study.
2) Novartis collaboration to develop SSTR2 radiopharmaceuticals
On November 18, Ratio Therapeutics announced that it had reached an exclusive global licensing and collaboration agreement with Novartis. This collaboration will leverage Ratio's expertise in radioligand therapy (RLT) discovery and development as well as its technology platform to jointly develop radiopharmaceuticals targeting somatostatin receptor 2 (SSTR2).
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
